Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients

Benzinga2021-12-14

Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-line lymphoma patients. The Company shared the data at the American Society of Hematology (ASH) Annual...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

HLTan
2021-12-14
HLTan
Ok
JonC1997
2021-12-14
JonC1997
Hi
- WMIING:
  Ok
- HyunBin:
  O

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1123768155?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-14 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123768155","market":"us","top_or_hot":-1,"title":"Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients","media":"Benzinga","content":"<div>\n<p>Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-line lymphoma patients.\n\nThe Company shared the data at the American Society of Hematology (ASH) Annual...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/12/24587185/gileads-car-t-yescarta-shows-78-complete-response-rate-in-first-line-lymphoma-patients\">网页链接</a>\n\n</div>\n","source":"lsy1606299360108","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGilead's CAR-T Yescarta Shows 78% Complete Response Rate In First-Line Lymphoma Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 20:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/12/24587185/gileads-car-t-yescarta-shows-78-complete-response-rate-in-first-line-lymphoma-patients><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-line lymphoma patients.\n\nThe Company shared the data at the American Society of Hematology (ASH) Annual...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/12/24587185/gileads-car-t-yescarta-shows-78-complete-response-rate-in-first-line-lymphoma-patients\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"https://www.benzinga.com/general/biotech/21/12/24587185/gileads-car-t-yescarta-shows-78-complete-response-rate-in-first-line-lymphoma-patients","article_id":"1123768155","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123768155","pubTimestamp":1639483311,"columns":[],"sourceInfo":{"source_id":"lsy1606299360108","name":"Benzinga"},"weMediaInfo":null,"summary":"Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-lin","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"Gilead的CAR-T Yescarta在一线淋巴瘤患者中显示78%的完全缓解率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":0.9},"content_text":"Kite Pharma, a Gilead Science Inc company, churned out more data for its CAR-T Yescarta in first-line lymphoma patients.\n\nThe Company shared the data at the American Society of Hematology (ASH) Annual Meeting & Exposition.\nIn updated results from the Phase 2 ZUMA-12 study, Yescarta posted a 78% complete response rate among 37 patients with high-risk large B cell lymphoma at a median follow-up of 15.9 months.\nAll median survival checkpoints hadn't been reached at a median of 15.9 months after infusion. Still, Kite floated 12-month outcomes estimates of 81% for durable responders, 73% for event-free survival, 75% for progression-free survival, and 91% for patients alive.\nOn the safety front, grade 3 or higher cytokine release syndrome occurred in 8% of patients, and 23% experienced a Grade 3 or higher neurological event.\nThere were no deaths tied to treatment with Yescarta, although one patient died from COVID-19.\nAll but one CRS and neurological events were resolved through treatment by the data cutoff.\nPrice Action: GILD shares closed at $70.61 on Monday.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":607392448,"gmtCreate":1639486053496,"gmtModify":1639486053693,"author":{"id":"3562631994362651","authorId":"3562631994362651","name":"HLTan","avatar":"https://static.tigerbbs.com/8d343018d7d670ebb323d39e98dd1a19","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562631994362651","authorIdStr":"3562631994362651"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607392448","repostId":1123768155,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":607309717,"gmtCreate":1639483533659,"gmtModify":1639483534052,"author":{"id":"3581841381174598","authorId":"3581841381174598","name":"JonC1997","avatar":"https://static.tigerbbs.com/3b36205562e7be603067005666045365","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3581841381174598","authorIdStr":"3581841381174598"},"htmlText":"Hi","listText":"Hi","text":"Hi","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/607309717","repostId":1123768155,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6978388,"gmtCreate":1639484178207,"gmtModify":1639484178323,"authorId":3554213821224025,"author":{"id":3554213821224025,"idStr":"3554213821224025","authorId":3554213821224025,"name":"WMIING","avatar":"https://static.tigerbbs.com/39217f40d9dc4a9a15fac00f34f63d83","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":607309717,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6978344,"gmtCreate":1639483704892,"gmtModify":1639483704995,"authorId":3581582714204773,"author":{"id":3581582714204773,"idStr":"3581582714204773","authorId":3581582714204773,"name":"HyunBin","avatar":"https://static.tigerbbs.com/d73c269ed706b06f2b386d6042cc1fd6","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":607309717,"type":1,"supId":0,"prevId":0,"content":"<u>O</u>","text":"<u>O</u>","html":"<u>O</u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":50,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123768155"}